Tenecteplase for the treatment of massive and submassive pulmonary embolism

Journal of Thrombosis and Thrombolysis

Volumn 18, Issue 1, 2004, Pages 47-50

  Melzer, Christoph ^a   Richter, Christoph ^a   Rogalla, Patrick ^a   Borges, Adrian Constantin ^a   Theres, Heinz ^a   Baumann, Gert ^a   Laule, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Pulmonary embolism; Tenecteplase; Thrombolysis

Indexed keywords

ALTEPLASE; HEPARIN; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLEEDING; BOLUS INJECTION; CASE REPORT; DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPNEA; FEMALE; FIBRINOLYTIC THERAPY; GENERAL CONDITION IMPROVEMENT; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; THROMBUS;

AGED; DYSPNEA; FEMALE; HUMANS; MIDDLE AGED; PULMONARY EMBOLISM; TISSUE PLASMINOGEN ACTIVATOR;

EID: 14944354287     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-004-0174-z     Document Type: Article

References (18)

1. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000;21:1301-1336.
2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389.
3. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143-1150.
4. Collen D, Stassen JM, Yasuda T, et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994;72:98-104.
5. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92:3032-3040.
6. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994;91:3670-3674.
7. Refino CJ, Paoni NF, Keyt BA, et al. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost 1993;70:313-319.
8. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716-722.
9. Van de Werf F, Barron HV, Armstrong PW, et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: A comparison of TNK-tPA and rt-PA. Eur Heart J 2001;22:2253-2261.
10. Sze DY, Carey MB, Razavi MK. Treatment of massive pulmonary embolus with catheter-directed tenecteplase. J Vasc Interv Radiol 2001;12:1456-1457.
11. Caldicott D, Parasivam S, Harding J, Edwards N, Bochner F. Tenecteplase for massive pulmonary embolus. Resuscitation 2002;55:211-213.
12. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997;77:346-349.
13. Goldhaber SZ, Haire WD, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507-511.
14. Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. JAMA 1976;236:1477-1480.
15. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a multicenter registry. Circulation 1997;96:882-888.
16. The urokinase pulmonary embolism trial. A national cooperative study. Circulation 1973;47:II1-108.
17. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992;20:520-526.
18. Tibbutt DA, Davies JA, Anderson JA, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J 1974;1:343-347.